Company intelligence / Profile preview
Dipexium Pharmaceuticals, Inc.
New York, New York, United States
- Ownership
- Public · DPRX
- Development stage
- Other
01
Overview
Dipexium's lead product Locilex (pexiganan cream 0.8%) failed to meet primary clinical endpoints in two Phase III studies in patients with mild diabetic foot ulcer infections. There was also evidence of a higher incidence of osteomyelitis and cellulitis in the Locilex treatment arms.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculePeptide
- Industry
- Biotech
02
Drug pipeline
1 asset03
Financials
- Market cap
- $9.5B
- Total revenue
- $5B
- Enterprise value
- $10.2B
Beyond the preview
Go deeper on Dipexium Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dipexium Pharmaceuticals, Inc..